ImageneBio, Inc. develops therapeutics for immunological, autoimmune and inflammatory diseases, led by IMG-007, a non-T cell-depleting, ADCC-silenced anti-OX40 receptor antagonist with an extended half-life. News about IMA centers on clinical program updates for atopic dermatitis and alopecia areata, preclinical data presentations, research and development spending, and financial results.
The company’s updates also cover financing activity, including private placements and pre-funded warrants, as well as governance and compensation matters such as inducement grants and management appointments. ImageneBio was formed and funded through a completed reverse merger with Ikena Oncology and a concurrent private placement in 2025.
ImageneBio (Nasdaq: IMA) reported Q1 2026 results and an IMG-007 program update on May 7, 2026. The company closed a ~$30 million private placement in April, which the company says extends cash runway into Q1 2028. IMG-007 moves forward in a ~400-patient Phase 2b ADAPTIVE trial with topline data expected in Q4 2027; a Phase 2 alopecia areata study is planned for 2026 with initial data expected in 2028.
Imagene (NASDAQ: IMA) entered a definitive securities purchase agreement for a private placement expected to raise approximately $30 million in gross proceeds on April 13, 2026. Proceeds will support further development of IMG-007 in alopecia areata and late-stage development activities in moderate-to-severe atopic dermatitis.
Pursuant to the offering, Imagene is selling pre-funded warrants to purchase up to 5,770,335 shares at $5.199 per warrant, with an exercise price of $0.001 per share. The transaction is led by Coastlands Capital with participation from new and existing investors; Leerink Partners is sole placement agent.
ImageneBio (Nasdaq: IMA) announced inducement equity grants on March 16, 2026 to two newly hired employees under its 2025 Inducement Plan. The grants total 38,442 RSUs and 43,000 NSOs with NSO exercise price set at $6.20 per share.
The NSOs vest over four years (25% at one year, then monthly over 36 months). RSUs vest in equal annual installments over four years. Awards are subject to the 2025 Inducement Plan and individual award agreements.
ImageneBio (Nasdaq: IMA) reported Q4 and full-year 2025 results and provided program and corporate updates. Key highlights: IMG-007 Phase 2b ADAPTIVE trial is enrolling with topline data expected in 2027, >150 subjects dosed to date, and a favorable blinded safety review in March 2026. The company ended 2025 with $135.3M in cash and equivalents.
ImageneBio (NASDAQ: IMA) will participate in the 2026 Leerink Global Healthcare Conference in Miami, March 8-11. Management will join a fireside chat on March 10 at 3:00 PM EST and hold one-on-one meetings. A webcast will be available and archived for 90 days on the company events page.
ImageneBio (Nasdaq: IMA) named Dr. Ben Porter-Brown as Chief Medical Officer, effective Feb 16, 2026. Dr. Porter-Brown brings 20+ years in autoimmune and inflammatory drug development, including leadership on OX40/OX40L programs. He will lead the clinical organization and drive completion and international expansion of the Phase 2b ADAPTIVE trial for atopic dermatitis (IMG-007). The company agreed to grant 137,000 shares as an inducement, subject to UK subsidiary employment and Nasdaq Rule 5635(c)(4).
ImageneBio (Nasdaq: IMA) reported third quarter 2025 results and provided program updates for IMG-007 on Nov 12, 2025. The company held $142.6 million in cash, cash equivalents, and marketable securities as of Sept 30, 2025, after a completed reverse merger and a concurrent $75.0 million private placement. R&D and G&A expenses rose to $15.6M and $11.0M for Q3, driving a $24.8M net loss. IMG-007 showed clinical activity in alopecia areata and strong AD signals (mean EASI -77% at week 16) in Phase 1b/2a; a Phase 2b ADAPTIVE trial protocol amendment is planned and topline data is expected in 2027. Leadership was strengthened with a new CEO, CTO, CSO/Ops, and an independent audit-chair director.
ImageneBio (Nasdaq: IMA) announced management will participate in fourth-quarter 2025 investor conferences with live webcasts and archived recordings available on the company investor relations site.
Scheduled appearances: Stifel Healthcare Conference fireside chat on Thursday, November 13, 2025 at 9:20 AM ET in New York, and Piper Sandler 37th Annual Healthcare Conference fireside chat on Thursday, December 4, 2025 at 10:00 AM ET in New York.
ImageneBio (Nasdaq: IMA), a clinical stage biotech company focused on immunological and inflammatory diseases, has granted significant inducement equity awards to its new CEO, Dr. Kristin Yarema. The compensation package includes 436,080 stock options at an exercise price of $16.37 per share and 153,505 restricted stock units (RSUs).
The awards, granted on July 28, 2025, feature a four-year vesting schedule with 25% vesting after one year and the remaining 75% vesting over subsequent periods. The stock options have a ten-year term, while RSUs will vest quarterly after the initial one-year cliff. All awards are contingent on Dr. Yarema's continued service with the company.
ImageneBio, Inc. (NASDAQ: IMA) has completed its merger with Ikena Oncology, combining their operations with a concurrent $75 million private placement from investors including Deep Track Capital, Foresite Capital, and RTW Investments. The merged entity will begin trading on July 28, 2025, under the ticker symbol "IMA".
The transaction includes a 1-for-12 reverse stock split of Ikena's common stock. Post-merger ownership structure comprises 43.1% Inmagene legacy holders, 35.3% Ikena legacy holders, and 21.6% new investors, with approximately 11.6 million shares outstanding. The company, led by CEO Dr. Kristin Yarema, will continue developing IMG-007, a non-depleting anti-OX40 monoclonal antibody, with Phase 2b topline data in atopic dermatitis expected in Q4 2026.